Wednesday , October 28 2020
Home / T. Cowen: Marginal Revolution
The author Tyler Cowen
Tyler Cowen
Tyler Cowen is an American economist, academic, and writer. He occupies the Holbert C. Harris Chair of economics as a professor at George Mason University and is co-author, with Alex Tabarrok, of the popular economics blog Marginal Revolution. Cowen and Tabarrok have also ventured into online education by starting Marginal Revolution University. He currently writes the "Economic Scene" column for the New York Times, and he also writes for such publications as The New Republic, the Wall Street Journal, Forbes, Newsweek, and the Wilson Quarterly.

T. Cowen: Marginal Revolution

Sunday assorted links

1. Mathematician Gary Cornell argues that current testing procedures won’t tell us much about vaccine efficacy for the elderly. 2. Nanobodies against Covid? 3. Markets in everything. 4. Indian labor regulations are really bad. 5. Strikingly good piece on Palantir (NYT), with cameos from Hegel, Talcott Parsons, Thiel, and Tolkien.  And Palantir. 6. Thwarted Santa vaccine markets in everything. The post Sunday assorted links appeared first on Marginal REVOLUTION.

Read More »

The class culture that is Britain

Universities must act to eradicate discrimination against working-class students, including the mockery of regional accents, equality campaigners have said. A Guardian investigation has found widespread evidence of students at some of the country’s leading universities being ridiculed over their accents and backgrounds, in some cases prompting them to leave education…. The Social Mobility Commission (SMC), which monitors progress in improving social mobility in the UK, described the...

Read More »

Saturday assorted links

1. More on the multiple vaccines problem.  And sitting in on the FDA vaccine panel meeting.  And Arthur W. Baker, EV winner for his work on vaccines, now has a home page. 2. Escaped cloned female mutant crayfish take over Belgian cemetery. 3. Matthew Aucoin on Boulez. 4. The German tilt-and-turn window.  And Germany moves to improve ventilation. 5. Krugman short paper on the Trump trade war (analytical, not polemic). 6. Slovakia is trying to test everyone, and quickly (WSJ). The post Saturday...

Read More »

How to Vaccinate and Continue Clinical Trials

According to Helen Branswell writing at STAT: There are serious signs the Food and Drug Administration is getting cold feet over the notion of issuing emergency use authorizations to allow for the widespread early deployment of Covid-19 vaccines. …“We are concerned about the risk that use of a vaccine under an EUA would interfere with long-term assessment of safety and efficacy in ongoing trials and potentially even jeopardize product approval,” Gruber said. “And not only the first...

Read More »

Minimum wage laws during a pandemic

From Michael Strain at Bloomberg: In July 2019, the nonpartisan Congressional Budget Office estimated that a $15 minimum wage would eliminate 1.3 million jobs. The CBO also forecast that such an increase would reduce business income, raise consumer prices, and slow the economy. The U.S. economy will be very weak throughout 2021. The nation will need more business income, not less; more jobs, not fewer; and faster, not slower, economic growth. A $15 minimum wage would move the economy in the...

Read More »

From the comments, on HCTs

The box most bioethicists are in is so small their thinking can’t extend beyond a few target people. In this case, the control group in a vaccine trial. The subjects could be paid for the risk, which is what we do for jobs all the time. Those risk/reward amounts for risky jobs are used to make estimates for the value of human life. Life insurance would allow high-risk people (us geezers) to join the trials. Their box doesn’t even consider human challenge trials (HCT) that give you...

Read More »

The AstraZeneca trial is allowed to resume

Federal health regulators have decided to allow the resumption of U.S. studies of a leading Covid-19 vaccine candidate from AstraZeneca PLC and the University of Oxford, according to a person familiar with the matter and materials reviewed by The Wall Street Journal. Here is the WSJ article, no real explanation given by either the company or the FDA. The post The AstraZeneca trial is allowed to resume appeared first on Marginal REVOLUTION.

Read More »